SMO and medulloblastoma: Expression of the G12V mutation of pro-oncogene HRAS or HRAS (G12V) and V600E mutations of BRAF induced resistance to SMO inhibitors, such as sonidegib, vismodegib, and LEQ-506, in Shh-subtype medulloblastoma (SMB) cells [139].